Jason P. Rhodes, Director at Dyne Therapeutics, Inc. (DYN), sold 2,586,928 shares at $26.20 ($65.2M) on 2026-08-13, disclosed to the SEC on 2026-08-17.
Scheduled sale ($65.2M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $26.20 | 63,643 | $1.7M | 2.6% |
| 2 | $26.20 | 94,415 | $2.5M | 3.8% |
| 3 | $26.20 | 268,354 | $7.0M | 10.8% |
| 4 | $25.00 | 322,465 | $8.1M | 12.4% |
| 5 | $25.00 | 478,377 | $12.0M | 18.3% |
| 6 | $25.00 | 1,359,674 |
| $34.0M |
| 52.1% |
| Total | $25.20 avg | 2,586,928 | $65.2M | 100% |
| Filing → |
| DYN | SELL | 2026-06-26 | $5.6M | — | Filing → |
| DYN | SELL | 2026-05-06 | $1.9M | — | Filing → |
| DYN | SELL | 2026-04-30 | $4.2M | — | Filing → |